What top creators are saying about United Therapeutics Corporation(UTHR)

Aggressively scaling organ manufacturing with FDA trials for Xenokidney and XenoHeart, opening commercial-scale facilities, and expanding into thymic rejuvenation and autologous organs for long-term growth

Offers strong exposure to high-barrier synthetic biology and organ manufacturing markets with upcoming catalysts including commercial facility expansions and clinical trials for xenotransplantation and autologous organ engineering.

Partnering with Varda Space to manufacture pharmaceuticals in microgravity for improved protein crystallization.

Investing heavily in xenografts (pig-grown organs), which could disrupt the organ transplant market.

The speaker has been bearish on the stock but admits it was a poor decision because the company has been 'really good at executing,' highlighting the risk of shorting well-run companies.

The speaker describes it as a 'weird company' and wonders when its 'miracle run will end' because its drugs have no patent life left. This makes its long-term cash flow questionable and could make it a 'good short'.